Novelix Pharmaceuticals Ltd

📊 Novelix Pharma Q3 FY26 Results: ₹4,840.27 Lakh Revenue with ₹100.44 Lakh Net Profit

• Total income of ₹4,840.27 lakh for Q3 FY26 (quarter ended Dec 31, 2025)

• Net profit of ₹100.44 lakh for Q3 FY26

• Allotted 23,20,000 equity shares via preferential issue at ₹60 per share, raising ₹13.92 crore

• Shares allotted to 36 investors including promoter group and non-promoters

• Top allottees: Pavani Vupparapalli (3,25,000 shares), Venkataramana Reddy Mallela (3,30,000 shares)

• Paid-up equity capital increased from ₹17.62 crore to ₹19.94 crore post-allotment

• Company operates in pharmaceutical research, manufacturing, and trading of active pharmaceutical ingredients